TANABE MITSUBISHI PHARMACEUTICAL CO., LTD. (Headquarters: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter referred to as "Tanabe Mitsubishi Pharmaceutical"), a member of the Mitsubishi Chemical Group, will begin recruiting for the 13th term of the "Tanabe Mitsubishi Pharmaceutical Palm Partner Program" from October 1, 2024, as part of its corporate citizenship activities to improve the quality of life (QOL) for patients with rare diseases and their supporting organizations, such as their medical care, education, employment, and daily life.

Tanabe Mitsubishi Pharmaceutical has the mission of providing hopeful options to all those facing illness. Despite the availability of pharmaceuticals from companies around the world, there are still many rare diseases that cannot be cured. Tanabe Mitsubishi Pharmaceutical considers it our important mission to conduct research and development of new drugs for these rare diseases and provide support to patients and their families who suffer from these illnesses. To this end, we established the "Tanabe Mitsubishi Pharmaceutical Palm Partner Program" in 2012 and have been providing grants to rare disease patient groups and their support organizations since fiscal year 2013.

The lives of patients and their families are not only about fighting the disease, but also about the irreplaceable daily moments of life itself. We hope that this program will support your battle with the disease and be a stepping stone to fulfilling each individual's sense of purpose and dreams for the future. We look forward to receiving applications from many organizations.

[PDF: 681KB]

News for 2024